CoSolve

Finding bold and innovative solutions to transform patients' lives


CoSolve is a global, virtual, Open Innovation challenge at AstraZeneca, seeking to find new collaborators – those with the boldest innovations and solutions that can accelerate the creation of the next wave of medicines to help transform patients’ lives.

 


Helping us find real solutions for real challenges we face

At AstraZeneca, we know that however innovative our science, however effective our medicines and delivery, to achieve all we want to achieve, we cannot do it alone.

CoSolve is a bi-annual initiative that breaks down the traditional barriers to collaboration and to find ideas that are immediately translatable. Each challenge is about helping us accelerate our delivery to get the right treatments to the right patients.

We are looking for innovators, particularly from start-ups and early-stage biotechs, with the ability and freedom of operation to rapidly progress their idea into a full project in real time with support from AstraZeneca.



Are you the innovator we need?

 

 

 

The CoSolve challenges are now OPEN. This current round closes on 14th May 2021.

 

Countdown to when the CoSolve round closes


The Challenges

In this round, there are seven challenges, spanning some of our key therapy areas, and science and technology platforms. New challenges will be announced every six months, so please sign up to our newsletter or keep checking back if your idea or innovation isn’t featured this time. The challenges are:


Gut microbiome modification to influence lung inflammation and/or immunity

We are seeking innovative ideas on how to modify the gut microbiome, particularly the gut-lung axis to specifically treat or prevent respiratory diseases or infections causing lung inflammation. These could include, but are not limited to, pre/probiotics and live bacterial products. 

Broad-spectrum antiviral agents

We are seeking novel solutions for broad spectrum antiviral agents and treatments, with the potential for rapid adaptation to novel viral evolving conditions. This could be a novel technology, small or large molecules, or a different breakthrough idea. 

Novel technologies to assess key aspects of health-related quality of life for patients with renal disease or heart failure

We are seeking novel technologies for remote assessments, such as wearables, sensors and digital biomarkers, that can collect more reliable, valid and responsive health-relevant data from patients living with renal disease or heart failure. The innovation could be the ability to monitor endpoints in clinical trials and research, or solutions for disease management in clinical practice, as a digital therapeutic. 

Technologies to enable patient-centric administration for next generation macromolecular therapies

We want innovative solutions to improve the patient experience in cardiovascular, renal and metabolic diseases, with new formulations, drug delivery and/or device approaches, and capabilities for oral delivery of peptide and nucleic acid therapeutics. 

Orally bioavailable small molecule agonists of Class B G-protein-coupled receptors (GPCRs)

We are seeking novel ideas on how to develop orally bioavailable small molecule agonists for Class B GPCRs, as potential new therapies for the treatment of metabolic disease, including type 2 diabetes. 

Regulatory T cell therapy for the treatment of immune-mediated diseases

We are looking for innovative solutions focused on building capabilities for off-the-shelf regulatory T (Treg) cell therapies, maintaining a stable and functional Treg in vivo, or inducing targeted Treg tissue delivery and activation. 

Targeting endogenous immune ‘brakes’ to restore immune homeostasis

We are seeking innovative ideas for identifying pathways and developing new targeted therapies to induce and sustain the immunomodulatory functions of diverse types of immune cells that are involved in immune equilibrium, or disrupted in autoimmune disease.


How does CoSolve work?

CoSolve is all about speed. We are looking for solutions that can be put into practice in a 12-18 month timeframe. Selected partners will be innovators with the ability and freedom of operation to rapidly progress their idea into a full project with support from AstraZeneca. The key steps in the process are: